Cargando…

Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate

Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamad, Issa, Abu Hejleh, Taher, Abdelqader, Sania, Wahbeh, Lina, Taqash, Ayat, Almousa, Abdelatif, Mayta, Ebrahim, Al-Ibraheem, Akram, Abuhijla, Fawzi, Abu-Hijlih, Ramiz, Hussein, Tariq, Al-Gargaz, Wisam, Ghatasheh, Hamza, Hosni, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145776/
https://www.ncbi.nlm.nih.gov/pubmed/37109315
http://dx.doi.org/10.3390/jcm12082979
_version_ 1785034418306416640
author Mohamad, Issa
Abu Hejleh, Taher
Abdelqader, Sania
Wahbeh, Lina
Taqash, Ayat
Almousa, Abdelatif
Mayta, Ebrahim
Al-Ibraheem, Akram
Abuhijla, Fawzi
Abu-Hijlih, Ramiz
Hussein, Tariq
Al-Gargaz, Wisam
Ghatasheh, Hamza
Hosni, Ali
author_facet Mohamad, Issa
Abu Hejleh, Taher
Abdelqader, Sania
Wahbeh, Lina
Taqash, Ayat
Almousa, Abdelatif
Mayta, Ebrahim
Al-Ibraheem, Akram
Abuhijla, Fawzi
Abu-Hijlih, Ramiz
Hussein, Tariq
Al-Gargaz, Wisam
Ghatasheh, Hamza
Hosni, Ali
author_sort Mohamad, Issa
collection PubMed
description Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (FCRR) and overall survival (OS), and secondary endpoints were 2-year disease-free survival (DFS), local failure (LF), regional failure (RF), distant metastases (DM), and RTOG grade 3 ≥ late toxicities. Adjuvant and definitive rRT were delivered to 22 and 27 patients, respectively. A total of 91% of patients were managed with conventional re-RT and 71% of patients received concurrent chemotherapy. The median follow-up after rRT was 30 months. The 2-year FCRR, OS, DFS, LF, RF, and DM were 64%, 51%, 28%, 32%, 9%, and 39% respectively. MVA showed that poor performance status (PS: 1–2 vs. 0) and age > 52 years were predictive of worse OS. In comparison, poor PS (1–2 vs. 0) and total dose of rRT < 60 Gy were predictive of worse DFS. Late RTOG toxicity of grade 3 ≥ was reported in nine (18.3%) patients. FCRR at 2 years after salvage rRT for rHNC was higher than other traditional endpoints and could be an important endpoint to be included in future rRT studies. rRT for rHNC at our cohort was relatively successful, with a manageable level of late severe toxicity. Replacing this approach in other developing countries is a viable option.
format Online
Article
Text
id pubmed-10145776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101457762023-04-29 Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate Mohamad, Issa Abu Hejleh, Taher Abdelqader, Sania Wahbeh, Lina Taqash, Ayat Almousa, Abdelatif Mayta, Ebrahim Al-Ibraheem, Akram Abuhijla, Fawzi Abu-Hijlih, Ramiz Hussein, Tariq Al-Gargaz, Wisam Ghatasheh, Hamza Hosni, Ali J Clin Med Article Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (FCRR) and overall survival (OS), and secondary endpoints were 2-year disease-free survival (DFS), local failure (LF), regional failure (RF), distant metastases (DM), and RTOG grade 3 ≥ late toxicities. Adjuvant and definitive rRT were delivered to 22 and 27 patients, respectively. A total of 91% of patients were managed with conventional re-RT and 71% of patients received concurrent chemotherapy. The median follow-up after rRT was 30 months. The 2-year FCRR, OS, DFS, LF, RF, and DM were 64%, 51%, 28%, 32%, 9%, and 39% respectively. MVA showed that poor performance status (PS: 1–2 vs. 0) and age > 52 years were predictive of worse OS. In comparison, poor PS (1–2 vs. 0) and total dose of rRT < 60 Gy were predictive of worse DFS. Late RTOG toxicity of grade 3 ≥ was reported in nine (18.3%) patients. FCRR at 2 years after salvage rRT for rHNC was higher than other traditional endpoints and could be an important endpoint to be included in future rRT studies. rRT for rHNC at our cohort was relatively successful, with a manageable level of late severe toxicity. Replacing this approach in other developing countries is a viable option. MDPI 2023-04-19 /pmc/articles/PMC10145776/ /pubmed/37109315 http://dx.doi.org/10.3390/jcm12082979 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mohamad, Issa
Abu Hejleh, Taher
Abdelqader, Sania
Wahbeh, Lina
Taqash, Ayat
Almousa, Abdelatif
Mayta, Ebrahim
Al-Ibraheem, Akram
Abuhijla, Fawzi
Abu-Hijlih, Ramiz
Hussein, Tariq
Al-Gargaz, Wisam
Ghatasheh, Hamza
Hosni, Ali
Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title_full Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title_fullStr Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title_full_unstemmed Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title_short Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
title_sort re-irradiation for recurrent head and neck cancer: freedom from cancer recurrence rate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145776/
https://www.ncbi.nlm.nih.gov/pubmed/37109315
http://dx.doi.org/10.3390/jcm12082979
work_keys_str_mv AT mohamadissa reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT abuhejlehtaher reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT abdelqadersania reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT wahbehlina reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT taqashayat reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT almousaabdelatif reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT maytaebrahim reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT alibraheemakram reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT abuhijlafawzi reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT abuhijlihramiz reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT husseintariq reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT algargazwisam reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT ghatashehhamza reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate
AT hosniali reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate